Exagen Inc. (Nasdaq: XGN) announced the select preliminary unaudited financial results for the fourth quarter and full year of 2025, in line with previous guidance, showcasing robust performance in key financial metrics.
The outstanding results include a record-breaking revenue surge of over 19% in 2025, significant Average Selling Price (ASP) expansion for AVISE CTD, double-digit test volume growth, and a year-end cash balance of $32 million, indicating exceptional financial management and operational efficiency.
The remarkable financial achievements in 2025 were propelled by the exceptional execution and progress made by Exagen's commercial, scientific, and operational teams, underscoring the company's strategic focus and operational excellence.
Record Revenue Growth
Exagen achieved a remarkable revenue growth of at least 19% in 2025 compared to the previous year, demonstrating strong market positioning and effective revenue generation strategies.
AVISE CTD Performance
The performance of AVISE CTD in 2025 exhibited a substantial ASP expansion of over $30 from 2024 levels, accompanied by a noteworthy test volume growth of at least 11%, indicating strong demand and market acceptance for Exagen's diagnostic offerings.
Financial Position
Exagen ended 2025 with cash and cash equivalents of $32 million, reflecting a $10 million increase from the prior year, highlighting sound financial management and liquidity management practices.
- Exagen's exceptional financial results in 2025 underscore its successful revenue growth and strategic advancements within the autoimmune diagnostics segment, positioning the company as a key player in the industry and showcasing its ability to capitalize on market opportunities and customer needs.
- The focus on innovation, operational efficiency, and prudent cash management has positioned Exagen favorably for sustained growth, enabling continued investments in research and development to drive future product innovation and market expansion.
Exagen's robust financial performance in 2025 not only demonstrates resilience and strategic acumen but also sets a solid foundation for future growth and innovation in the autoimmune diagnostics sector, reinforcing its position as a leading player in the market.